A phase I, open‐label, single‐dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib

Futibatinib is a covalently binding FGFR1–4 inhibitor that received US Food and Drug Administration approval for the treatment of patients with previously treated, advanced intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions/rearrangements. This phase I trial evaluated the pharmacokinetics...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Ling, Yamamiya, Ikuo, Pinti, Mark, Rondon, Juan Carlos, Marbury, Thomas, Tomlinson, Gareth, Makris, Lukas, Hangai, Nanae, Wacheck, Volker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499415/
https://www.ncbi.nlm.nih.gov/pubmed/37553804
http://dx.doi.org/10.1111/cts.13585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499415/
https://www.ncbi.nlm.nih.gov/pubmed/37553804
http://dx.doi.org/10.1111/cts.13585

Ejemplares similares